Wells Fargo’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q2 | – | Sell |
-2,270
| Closed | -$2K | – | 6898 |
|
|
2019
Q1 | $2K | Hold |
2,270
| – | – | ﹤0.01% | 5905 |
|
|
2018
Q4 | $2K | Sell |
2,270
-26,374
| -92% | -$39.7K | ﹤0.01% | 6243 |
|
|
2018
Q3 | $61K | Sell |
28,644
-755
| -3% | -$1.81K | ﹤0.01% | 5535 |
|
|
2018
Q2 | $68K | Buy |
29,399
+1,750
| +6% | +$5.1K | ﹤0.01% | 5514 |
|
|
2018
Q1 | $88K | Sell |
27,649
-1,037
| -4% | -$2.86K | ﹤0.01% | 5364 |
|
|
2017
Q4 | $118K | Buy |
28,686
+24,196
| +539% | +$105K | ﹤0.01% | 5240 |
|
|
2017
Q3 | $20K | Sell |
4,490
-6,084
| -58% | -$24.6K | ﹤0.01% | 5715 |
|
|
2017
Q2 | $35K | Sell |
10,574
-37,903
| -78% | -$157K | ﹤0.01% | 5501 |
|
|
2017
Q1 | $446K | Buy |
48,477
+28,977
| +149% | +$254K | ﹤0.01% | 4320 |
|
|
2016
Q4 | $150K | Sell |
19,500
-30,036
| -61% | -$276K | ﹤0.01% | 4922 |
|
|
2016
Q3 | $566K | Buy |
49,536
+36,910
| +292% | +$430K | ﹤0.01% | 3879 |
|
|
2016
Q2 | $155K | Sell |
12,626
-2,629
| -17% | -$31.9K | ﹤0.01% | 4551 |
|
|
2016
Q1 | $155K | Sell |
15,255
-383,239
| -96% | -$4.5M | ﹤0.01% | 4568 |
|
|
2015
Q4 | $8.98M | Buy |
398,494
+70,942
| +22% | +$1.45M | ﹤0.01% | 1917 |
|
|
2015
Q3 | $5.43M | Buy |
327,552
+308,890
| +1,655% | +$6.19M | ﹤0.01% | 2266 |
|
|
2015
Q2 | $420K | Buy |
18,662
+17,975
| +2,616% | +$443K | ﹤0.01% | 4201 |
|
|
2015
Q1 | $18K | Hold |
687
| – | – | ﹤0.01% | 5439 |
|
|
2014
Q4 | $15K | Buy |
687
+103
| +18% | +$2.11K | ﹤0.01% | 5491 |
|
|
2014
Q3 | $11K | Sell |
584
-316
| -35% | -$6.35K | ﹤0.01% | 5566 |
|
|
2014
Q2 | $21K | Buy |
900
+446
| +98% | +$11K | ﹤0.01% | 5367 |
|
|
2014
Q1 | $15K | Buy |
454
+150
| +49% | +$5.05K | ﹤0.01% | 5306 |
|
|
2013
Q4 | $9K | Sell |
304
-6,198
| -95% | -$114K | ﹤0.01% | 5236 |
|
|
2013
Q3 | $100K | Buy |
+6,502
| New | +$120K | ﹤0.01% | 4471 |
|
Wells Fargo's OMED Position: Q2 2019 in Review
Wells Fargo sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2019, closing a stake of 2,270 shares — an estimated $2K sold.
Wells Fargo first reported a position in OMED in Q3 2013 and held it in 23 quarters. The position peaked at $8.98M in Q4 2015. 0 funds tracked by Wall St. Rank hold OMED as of Q2 2019.
- Wells Fargo reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
- Wells Fargo sold 2,270 OncoMed Pharmaceuticals, Inc. shares in Q2 2019, an estimated $2K.
- Wells Fargo first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2013 and held it in 23 quarters.
- Wells Fargo's OncoMed Pharmaceuticals, Inc. position peaked at $8.98M in Q4 2015.
- 0 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2019.
Based on Wells Fargo's 13F filing for Q2 2019, filed 6 Aug 2019.